Takami Sato
Experienced in Hereditary Retinoblastoma

Dr. Takami Sato

Hematology | Oncology
111 South 11th Street, The Bodine Center, 
Philadelphia, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Hereditary Retinoblastoma
111 South 11th Street, The Bodine Center, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Takami Sato is an Oncologist in Philadelphia, Pennsylvania. Dr. Sato is rated as an Experienced provider by MediFind in the treatment of Hereditary Retinoblastoma. His top areas of expertise are Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, Liver Embolization, and Osteotomy. Dr. Sato is currently accepting new patients.

His clinical research consists of co-authoring 96 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Jichi Medical School
Residency
Oita Prefectural Hospital
Specialties
Hematology
Oncology
Licenses
Internal Medicine in PA
Fellowships
Jichi Medical School
Hospital Affiliations
Thomas Jefferson University Hospital
Languages Spoken
English
Japanese
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
View 6 Less Insurance Carriers -

Locations

111 South 11th Street, The Bodine Center, Philadelphia, PA 19107
Other Locations
Jefferson Cancer - Honickman Center
1101 Chestnut Street, Floor 14, Philadelphia, PA 19107

Additional Areas of Focus

Dr. Sato has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Melanoma
Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers
Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers
Enrollment Status: Recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-Label, Single Institution, Phase II Study Using Radioactive Yttrium90 Microsphere (SIR-Sphere®) in Uveal Melanoma Patients With Hepatic Metastasis
An Open-Label, Single Institution, Phase II Study Using Radioactive Yttrium90 Microsphere (SIR-Sphere®) in Uveal Melanoma Patients With Hepatic Metastasis
Enrollment Status: Completed
Publish Date: November 14, 2025
Intervention Type: Device
Study Phase: Phase 2
A Phase II Trial of Defactinib (VS-6063) Combined With VS-6766 (CH5126766) in Patients With Metastatic Uveal Melanoma
A Phase II Trial of Defactinib (VS-6063) Combined With VS-6766 (CH5126766) in Patients With Metastatic Uveal Melanoma
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug, Procedure
Study Drugs: Defactinib Hydrochloride, Raf/MEK Inhibitor VS-6766
Study Phase: Phase 2
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Radiation, Drug
Study Drug: MK-3475
Study Phase: Phase 1
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: IMCgp100
Study Phase: Phase 1/Phase 2
A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer
A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer
Enrollment Status: Terminated
Publish Date: March 11, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Feasibility Study of Sequential Hepatic Internal Radiation and Systemic Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastatic to Liver.
A Feasibility Study of Sequential Hepatic Internal Radiation and Systemic Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastatic to Liver.
Enrollment Status: Unknown
Publish Date: April 19, 2021
Intervention Type: Drug, Device
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma
An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma
Enrollment Status: Terminated
Publish Date: September 03, 2020
Intervention Type: Biological, Other
Study Phase: Phase 1
View 7 Less Clinical Trials

99 Total Publications

Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 12, 2025
Similar Doctors
Carol L. Shields
Elite in Hereditary Retinoblastoma
Dr. Carol L. Shields
Ophthalmology | Oncology
Elite in Hereditary Retinoblastoma
Dr. Carol L. Shields
Ophthalmology | Oncology

Ophthalmology - Wills Eye Hospital

840 Walnut Street, Floor 10, 
Philadelphia, PA 
 (0.2 miles away)
215-928-3105
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Carol Shields is an Oncologist and an Ophthalmologist in Philadelphia, Pennsylvania. Dr. Shields is rated as an Elite provider by MediFind in the treatment of Hereditary Retinoblastoma. Her top areas of expertise are Retinoblastoma, Melanoma of the Eye, Uveal Melanoma, Vitrectomy, and Iridectomy. Dr. Shields is currently accepting new patients.

Advanced in Hereditary Retinoblastoma
Dr. Sarah J. Easaw
Oncology | Hematology
Advanced in Hereditary Retinoblastoma
Dr. Sarah J. Easaw
Oncology | Hematology
1255 Route 70, 31 S, 
Lakewood, NJ 
 (52.3 miles away)
732-961-0010
Languages Spoken:
English, Malayalam
See accepted insurances
Accepting New Patients

Sarah Easaw is an Oncologist and a Hematologist in Lakewood, New Jersey. Dr. Easaw is rated as a Distinguished provider by MediFind in the treatment of Hereditary Retinoblastoma. Her top areas of expertise are Myelodysplastic Syndrome (MDS), RUNX1 Familial Platelet Disorder, Paget Disease of the Breast, and Breast Cancer. Dr. Easaw is currently accepting new patients.

Advanced in Hereditary Retinoblastoma
Dr. Amish Shah
Pediatrics | Hematology | Oncology
Advanced in Hereditary Retinoblastoma
Dr. Amish Shah
Pediatrics | Hematology | Oncology

Childrens Health Care Associates Inc

3401 Civic Ctr Blvd, 
Philadelphia, PA 
 (2.0 miles away)
215-590-1000
Experience:
18+ years
Languages Spoken:
English
See accepted insurances

Amish Shah is a Pediatrics specialist and a Hematologist in Philadelphia, Pennsylvania. Dr. Shah has been practicing medicine for over 18 years and is rated as an Advanced provider by MediFind in the treatment of Hereditary Retinoblastoma. His top areas of expertise are Retinoblastoma, Neurofibromatosis, Neurofibromatosis Type 1 (NF1), and Hereditary Retinoblastoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sato's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile